Literature DB >> 16096369

High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma.

Zhi-Gang Pan1, V I Kashuba, Xiao-Qiong Liu, Jian-Yong Shao, Ru-Hua Zhang, Ju-Hong Jiang, Can Guo, Eugene Zabarovsky, Ingemar Ernberg, Yi-Xin Zeng.   

Abstract

High frequency loss of 3p21.3 region is a common event in various kinds of tumors including nasopharyngeal carcinoma (NPC). RASSF1A has been identified as a putative tumor suppressor gene residing in this region. Chromosome alterations and epigenetic changes are commonly observed as mechanisms for inactivation of RASSF1A function. In this study, we applied the PCR-cloning-sequencing strategy to examine somatic mutations in RASSF1A in NPC tissues as compared with the sequences detected in the matched peripheral blood lymphocytes. Our results revealed a high incidence of RASSF1A mutation in primary tumor tissues of NPC. There are totally 35 mutations identified in 74% (17/23) of these NPC cases, including 30 transitions, three transversions and two deletions. Most of these mutations result in amino acid changes: three nonsense (stop codon) mutations, two-1 bp deletion (frameshift), 26 missense and the remaining four are synonymous (silent). No obvious 'hot-spot' mutations were observed in this study. A similarly high rate (74%) of promoter methylation of RASSF1A was also detected in the same group of NPC tissues, but no significant correlation between mutation and methylation was detected. Our results suggest various mechanisms involved in inactivation of RASSF1A function and indicate a critical role of RASSF1A in NPC development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096369     DOI: 10.4161/cbt.4.10.2023

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  15 in total

1.  Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.

Authors:  He-Ling Wang; Yu Zhang; Peng Liu; Ping-Yi Zhou
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

2.  Molecular classification and molecular targeted therapy of cancer.

Authors:  Miao Xu; Jianyong Shao; Yixin Zeng
Journal:  Front Med       Date:  2013-06       Impact factor: 4.592

3.  Benzo[a]pyrene decreases global and gene specific DNA methylation during zebrafish development.

Authors:  Xiefan Fang; Cammi Thornton; Brian E Scheffler; Kristine L Willett
Journal:  Environ Toxicol Pharmacol       Date:  2013-02-28       Impact factor: 4.860

4.  Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer.

Authors:  Vera N Senchenko; Ekaterina A Anedchenko; Tatiana T Kondratieva; George S Krasnov; Alexei A Dmitriev; Veronika I Zabarovska; Tatiana V Pavlova; Vladimir I Kashuba; Michael I Lerman; Eugene R Zabarovsky
Journal:  BMC Cancer       Date:  2010-03-01       Impact factor: 4.430

5.  RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression.

Authors:  Rosalyn R Ram; Saurabh Mendiratta; Brian O Bodemann; Michael J Torres; Ugur Eskiocak; Michael A White
Journal:  Mol Cell Biol       Date:  2014-04-14       Impact factor: 4.272

Review 6.  Ras signaling through RASSF proteins.

Authors:  Howard Donninger; M Lee Schmidt; Jessica Mezzanotte; Thibaut Barnoud; Geoffrey J Clark
Journal:  Semin Cell Dev Biol       Date:  2016-06-08       Impact factor: 7.727

7.  SCC-112 gene is involved in tumor progression and promotes the cell proliferation in G2/M phase.

Authors:  M Z Zheng; L M Zheng; Y X Zeng
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-11       Impact factor: 4.553

8.  Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.

Authors:  Zhaohui Wang; Lili Li; Xianwei Su; Zifen Gao; Gopesh Srivastava; Paul G Murray; Richard Ambinder; Qian Tao
Journal:  J Transl Med       Date:  2012-10-11       Impact factor: 5.531

9.  RASSF1 Polymorphisms in Cancer.

Authors:  Marilyn Gordon; Mohamed El-Kalla; Shairaz Baksh
Journal:  Mol Biol Int       Date:  2012-05-31

10.  High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer.

Authors:  Vladimir I Kashuba; Tatiana V Pavlova; Elvira V Grigorieva; Alexey Kutsenko; Surya Pavan Yenamandra; Jingfeng Li; Fuli Wang; Alexei I Protopopov; Veronika I Zabarovska; Vera Senchenko; Klas Haraldson; Tatiana Eshchenko; Julia Kobliakova; Olga Vorontsova; Igor Kuzmin; Eleonora Braga; Vladimir M Blinov; Lev L Kisselev; Yi-Xin Zeng; Ingemar Ernberg; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.